ArriVent BioPharma (AVBP) Current Leases (2023 - 2026)
ArriVent BioPharma (AVBP) posted Current Leases of $99000.0 for Q1 2026, up 607.14% sequentially from $14000.0 in Q4 2025, and down 28.26% YoY from $138000.0 in Q1 2025.
ArriVent BioPharma (AVBP) Current Leases (2023 - 2026) Analysis & Trends
ArriVent BioPharma has reported Current Leases for 4 years, with the latest figure at $99000.0 in Q1 2026.
- Quarterly Current Leases fell 28.26% year-over-year to $99000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $99000.0 (down 28.26% YoY) and the FY2025 annual result came in at $14000.0, down 91.36% from the prior year.
- Current Leases advanced to $99000.0 in Q1 2026 per AVBP's latest filing, from $14000.0 in the prior quarter.
- Over five years, Current Leases peaked at $162000.0 in Q4 2024 and troughed at $14000.0 in Q4 2025.
- A 4-year average of $116300.0 and a median of $139000.0 in 2023 frame the typical range for Current Leases.
- The sharpest annual moves came in 2024 and 2025: Current Leases increased 15.71% in 2024, then tumbled 91.36% in 2025.
- Over 4 years, Current Leases stood at $140000.0 in 2023, then advanced by 15.71% to $162000.0 in 2024, then sank by 91.36% to $14000.0 in 2025, then surged by 607.14% to $99000.0 in 2026.
- According to Business Quant data, Current Leases over the past three periods registered $99000.0, $14000.0, and $56000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 11.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 16.75 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 21.95 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 2.24 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 45.93 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.27 Mn |
| 10 | ArriVent BioPharma | 1.43 Bn | 1.43 Bn | - | 318,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 318,000.00 |
| Mar 31, 2026 | 99,000.00 |
| Dec 31, 2025 | 14,000.00 |
| Sep 30, 2025 | 56,000.00 |
| Jun 30, 2025 | 98,000.00 |
| Mar 31, 2025 | 138,000.00 |
| Dec 31, 2024 | 162,000.00 |
| Sep 30, 2024 | 157,000.00 |
| Jun 30, 2024 | 152,000.00 |
| Mar 31, 2024 | 147,000.00 |
| Dec 31, 2023 | 140,000.00 |